Top Ten articles in the Pharma Industry this week
pharmafile | September 30, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |
Coming towards the end of September, we’ve had some major developments in drug trials and bad news for some of the biggest names in the pharmacetuical industry. We’ve gone through our news stories and features to pick out the most read and the must-read stories of the week. You’re able to find the biggest news from the previous weeks in the newly released digital version of Pharmafocus.
10. UK Biopharma and life after Brexit
Paul Ranson, of global law firm Morgan Lewis’ London Life Sciences Practice examines how UK biopharma must now adapt to a changing landscape
9. Sanofi secures $43 million government funding for zika vaccine development
Funding from the BioMedical Advanced Research and Development Authority will be used to pursue mid-stage trials beginning in 2018.
8. GW Pharma release positive data on cannididoil-based Phase III trial
The London-based company has released more positive data from a Phase III trial for Epidiolex. The experimental cannabidiol drug has been used to positively treat seizures.
7. Johnson & Johnson’s Stelera receives FDA approval
The FDA gave approval to Johnson & Johnson’s psoriasis drug, Stelara, for use in adults with Crohn’s disease.
6. Amgen’s Kyprolis disappoints in Phase III trial
Amgen’s Kyprolis was supposed to be a market leader when it came to combating multiple myeloma but, in a recent Phase III trial, it was found to be no more effective than Velcade, an established competitor made by Takeda.
5. Johnson & Johnson failed to inform FDA over faulty blood testing device in Phase III trial
Janssen, the pharmaceutical arm of Johnson & Johnson, were aware of a faulty blood testing device used during a key Phase III trial and yet did not notify the FDA.
4. AbbVie and Eisai celebrate approval of new Humira indication
The anti-TNF-α monoclonal antibody formulation has been approved in Japan for the treatment of non-infectious intermediate, posterior and panuveitis regardless of underlying disease.
3. FDA gives green light to the first Humira biosimilar
The first biosimilar of the world’s second best-selling drug is edging closer to release with official FDA approval.
2. Zuckerberg appoints AstraZeneca’s Cornelia Bargmann
Cornelia Bargmann has been named as the president of science at the Chan Zuckerberg Initiative, a philanthropic company funded by Facebook’s Mark Zuckerberg and his wife Priscilla Chan.
1. 80% of Chinese Clinical trials’ data fabricated
China’s food and drug regulator recently carried out a one year long review of clinical trials and the resultant data, finding that the 80% of data was “fabricated”.
